Targeted News Service

Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes
September 09, 2024

NEW YORK, Sept. 9 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, issued the following news release:

Vancouver, BC, Canada and New York, September 9th, 2024 Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for autoimmune diseases, has received an award from Breakthrough T1D (formerly JDRF) to advance INT's technology to induce immune tolerance in type 1 diabetes (T1D).

INT's devel . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form